BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 29573334)

  • 1. FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro.
    Cha Y; Kim HP; Lim Y; Han SW; Song SH; Kim TY
    Mol Oncol; 2018 Jun; 12(7):993-1003. PubMed ID: 29573334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
    Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
    Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGFR2 is amplified in the NCI-H716 colorectal cancer cell line and is required for growth and survival.
    Mathur A; Ware C; Davis L; Gazdar A; Pan BS; Lutterbach B
    PLoS One; 2014; 9(6):e98515. PubMed ID: 24968263
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Carter JH; Cottrell CE; McNulty SN; Vigh-Conrad KA; Lamp S; Heusel JW; Duncavage EJ
    Cold Spring Harb Mol Case Stud; 2017 Nov; 3(6):. PubMed ID: 28835367
    [No Abstract]   [Full Text] [Related]  

  • 5. Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer.
    Huynh H; Ong R; Zopf D
    J Exp Clin Cancer Res; 2015 Oct; 34():132. PubMed ID: 26514182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
    Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
    BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification.
    Kim ST; Jang HL; Lee SJ; Lee J; Choi YL; Kim KM; Cho J; Park SH; Park YS; Lim HY; Yashiro M; Kang WK; Park JO
    Mol Cancer Ther; 2014 Nov; 13(11):2527-36. PubMed ID: 25249557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.
    Kunii K; Davis L; Gorenstein J; Hatch H; Yashiro M; Di Bacco A; Elbi C; Lutterbach B
    Cancer Res; 2008 Apr; 68(7):2340-8. PubMed ID: 18381441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells.
    Matsuoka K; Nakagawa F; Tanaka N; Okabe H; Matsuo K; Takechi T
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer.
    Liu YC; Tsai JJ; Weng YS; Hsu FT
    Biomed Pharmacother; 2020 Aug; 128():110319. PubMed ID: 32502841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regorafenib in metastatic colorectal cancer.
    Sartore-Bianchi A; Zeppellini A; Amatu A; Ricotta R; Bencardino K; Siena S
    Expert Rev Anticancer Ther; 2014 Mar; 14(3):255-65. PubMed ID: 24559322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer.
    Verstraete M; Debucquoy A; Gonnissen A; Dok R; Isebaert S; Devos E; McBride W; Haustermans K
    BMC Cancer; 2015 Dec; 15():946. PubMed ID: 26675289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer.
    Fan LC; Teng HW; Shiau CW; Tai WT; Hung MH; Yang SH; Jiang JK; Chen KF
    Oncotarget; 2016 Sep; 7(39):64136-64147. PubMed ID: 27580057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
    André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
    Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK.
    Lau DK; Luk IY; Jenkins LJ; Martin A; Williams DS; Schoffer KL; Chionh F; Buchert M; Sjoquist K; Boussioutas A; Hayes SA; Ernst M; Weickhardt AJ; Pavlakis N; Tebbutt NC; Mariadason JM
    Mol Cancer Ther; 2021 Apr; 20(4):704-715. PubMed ID: 33563752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.
    Konecny GE; Kolarova T; O'Brien NA; Winterhoff B; Yang G; Qi J; Qi Z; Venkatesan N; Ayala R; Luo T; Finn RS; Kristof J; Galderisi C; Porta DG; Anderson L; Shi MM; Yovine A; Slamon DJ
    Mol Cancer Ther; 2013 May; 12(5):632-42. PubMed ID: 23443805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ; Keisler MD; Walko CM
    Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models.
    Daudigeos-Dubus E; Le Dret L; Lanvers-Kaminsky C; Bawa O; Opolon P; Vievard A; Villa I; Pagès M; Bosq J; Vassal G; Zopf D; Geoerger B
    PLoS One; 2015; 10(11):e0142612. PubMed ID: 26599335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells.
    Grygielewicz P; Dymek B; Bujak A; Gunerka P; Stanczak A; Lamparska-Przybysz M; Wieczorek M; Dzwonek K; Zdzalik D
    Gastric Cancer; 2016 Jan; 19(1):53-62. PubMed ID: 25407459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis.
    Chen D; Wei L; Yu J; Zhang L
    Clin Cancer Res; 2014 Jul; 20(13):3472-84. PubMed ID: 24763611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.